% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{vanderVeere:285056,
      author       = {van der Veere, Pieter J and van Harten, Argonde C and van
                      Maurik, Ingrid S and Teunissen, Charlotte E and Barkhof,
                      Frederik and Vos, Stephanie J B and Froelich, Lutz and
                      Kornhuber, Johannes and Wiltfang, Jens and Maier, Wolfgang
                      and Peters, Oliver and Rüther, Eckart and Frisoni, Giovanni
                      B and Spiru, Luiza and Freund-Levi, Yvonne and Wallin, Åsa
                      K and Hampel, Harald and Tsolaki, Magda and Kłoszewska,
                      Iwona and Mecocci, Patrizia and Vellas, Bruno and Lovestone,
                      Simon and Galluzzi, Samantha and Herukka, Sanna-Kaisa and
                      Santana, Isabel and Baldeiras, I. and de Mendonca, Alexandre
                      and Silva, Dina and Chetelat, Gael and Poisnel, Géraldine
                      and Visser, Pieter Jelle and Johnson, Sterling C and
                      Stormrud, Erik and Hansson, Oskar and Palmqvist, Sebastian
                      and Piñol-Ripoll, Gerard and Berkhof, Johannes and van der
                      Flier, Wiesje M},
      collaboration = {Initiative, Alzheimer's Disease Neuroimaging},
      title        = {{R}evising the {ABIDE} {MCI} to dementia prediction model
                      for automated cerebrospinal fluid assays.},
      journal      = {Alzheimer's and dementia},
      volume       = {22},
      number       = {2},
      issn         = {1552-5260},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DZNE-2026-00180},
      pages        = {e71192},
      year         = {2026},
      abstract     = {Automated cerebrospinal fluid (CSF) biomarker assays have
                      largely replaced manual immunoassays for measuring amyloid
                      pathology in CSF. We refitted and validated the ABIDE model,
                      predicting progression from mild cognitive impairment (MCI)
                      to dementia, with CSF measurements from the automated
                      Elecsys platform.We included 2413 MCI participants (998
                      $[41\%]$ amyloid-positive) from seven observational cohorts.
                      Elecsys was used in 958 $(40\%)$ participants. The
                      parameters of the previous ABIDE Cox model were
                      re-estimated. Model discrimination and calibration were
                      evaluated with leave-one-cohort-out cross-validation.During
                      follow-up, 1034 $(42\%;$ 585 $[58\%]$ amyloid-positive)
                      participants developed dementia. Discrimination was good
                      with Harrell's C of 0.70 $(95\%$ confidence interval [CI]:
                      0.66-0.73). Calibration was good in the total population and
                      amyloid-positive subgroup, with substantial predicted
                      progression risks for all amyloid-positive participants.We
                      refitted the ABIDE model, predicting MCI to dementia
                      progression, with automated CSF measurements. The model was
                      well calibrated in amyloid-positive patients and may support
                      clinical discussions regarding ATTs.},
      keywords     = {Humans / Cognitive Dysfunction: cerebrospinal fluid /
                      Cognitive Dysfunction: diagnosis / Dementia: cerebrospinal
                      fluid / Dementia: diagnosis / Male / Female / Aged / Disease
                      Progression / Biomarkers: cerebrospinal fluid / Amyloid
                      beta-Peptides: cerebrospinal fluid / Cohort Studies / Aged,
                      80 and over / Alzheimer's disease (Other) / automated
                      cerebrospinal fluid assays (Other) / cerebrospinal fluid
                      (Other) / dementia (Other) / mild cognitive dementia (Other)
                      / prediction (Other) / Biomarkers (NLM Chemicals) / Amyloid
                      beta-Peptides (NLM Chemicals)},
      cin          = {AG Wiltfang / AG Wagner / AG Peters},
      ddc          = {610},
      cid          = {I:(DE-2719)1410006 / I:(DE-2719)1011201 /
                      I:(DE-2719)5000000},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41657128},
      doi          = {10.1002/alz.71192},
      url          = {https://pub.dzne.de/record/285056},
}